MorphoSys AG: MorphoSys Reports Preliminary Q2 2022 Monjuvi

Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million)Update of financial guidance range for 2022 Monjuvi U.S. net product sales (now US$ 90 to US$ 110 million)Update of

Related Keywords

Germany , Boston , Massachusetts , United States , Canada , United Kingdom , Planegg , Bayern , Kaitlyn Nealy , Thomas Biegi , Julia Neugebauer , Jean Paul Kress , Myles Clouston , Linkedin , Xencor Inc , Twitter , Drug Administration , Us Communications , Exchange Commission , Human Immunology Biosciences Inc , Human Immunology Biosciences , Product Sales , Chief Executive Officer , Gross Margin , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Morphosy Annual Report , Morphosys , Reports , Reliminary , 022 , Monjuvi , Sales , Updates , Financial , Guidance ,